Neuropilin-1 as therapeutic target for malignant melanoma

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Graziani, Grazia ^a   Lacal, Pedro M ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Angiogenesis; Cell penetrating peptides; Melanoma; Metastasis; Neuropilin 1; Peptidomimetics; T regulatory cells

Indexed keywords

B RAF KINASE INHIBITOR; CELL PENETRATING PEPTIDE; FIBROBLAST GROWTH FACTOR; INTEGRIN; MATRIX METALLOPROTEINASE; MICRORNA; NEUROPILIN 1; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SEMAPHORIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ASTROCYTOMA; CELL MIGRATION; CELL PROLIFERATION; COLON CARCINOMA; CUTANEOUS MELANOMA; DRUG TARGETING; ENZYME RELEASE; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; MELANOMA; NEUROBLASTOMA; NONHUMAN; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; PROTEIN BINDING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR INVASION;

EID: 84934277040     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00125     Document Type: Short Survey

References (105)

1. Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J (2008) 411:211-26. doi:10.1042/BJ20071639
2. Kolodkin A, Levengood D, Rowe E, Tai YT, Giger R, Ginty D. Neuropilin is a semaphorin III receptor. Cell (1997) 90:753-62. doi:10.1016/S0092-8674(00)80535-8
3. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell (1997) 90:739-51. doi:10.1016/S0092-8674(00)80534-6
4. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer (2008) 8:632-45. doi:10.1038/nrc2404
5. Gaur P, Bielenberg DR, Samuel S, Bose D, Zhou Y, Gray MJ, et al. Role of class 3 semaphorins and their receptors in tumor growth and angiogenesis. Clin Cancer Res (2009) 15:6763-70. doi:10.1158/1078-0432.CCR-09-1810
6. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development (1995) 121:4309-18.
7. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development (1999) 126:4895-902.
8. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem (1998) 273:22272-8. doi:10.1074/jbc.273.35.22272
9. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 92:735-45. doi:10.1016/S0092-8674(00)81402-6
10. Mäkinen T, Olofsson B, Karpanen T, Hellman U, Soker S, Klagsbrun M, et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem (1999) 274:21217-22. doi:10.1074/jbc.274.30.21217
11. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem (2000) 275:26690-5. doi:10.1074/jbc.M003955200
12. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J Biol Chem (2000) 275:18040-5. doi:10.1074/jbc.M909259199
13. Kärpänen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J (2006) 20:1462-72. doi:10.1096/fj.05-5646com
14. Ballmer-Hofer K, Andersson AE, Ratcliffe LE, Berger P. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood (2011) 118:816-26. doi:10.1182/blood-2011-01-328773
15. Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, Tkachenko EV, et al. Selective regulation of arterial branching morphogenesis by synectin. Dev Cell (2006) 10:783-95. doi:10.1016/j.devcel.2006.03.012
16. Prud'homme GJ, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget (2012) 3:921-39.
17. Chaudhary B, Elkord E. Novel expression of neuropilin 1 on human tumor-infiltrating lymphocytes in colorectal cancer liver metastases. Expert Opin Ther Targets (2014) 29:1-15. doi:10.1517/14728222.2014.977784
18. Matsushita A, Gotze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res (2007) 67:10309-16. doi:10.1158/0008-5472.CAN-07-3256
19. Wild JRL, Staton CA, Chapple K, Corfe BM. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol (2012) 93:81-103. doi:10.1111/j.1365-2613.2012.00810.x
20. Fukasawa M, Matsushita A, Korc M. Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther (2007) 6:1173-80. doi:10.4161/cbt.6.8.4363
21. Robinson SD, Reynolds LE, Kostourou V, Reynolds AR, da Silva RG, Tavora B, et al. Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem (2009) 284:33966-81. doi:10.1074/jbc.M109.030700
22. Valdembri D, Caswell PT, Anderson KI, Schwarz JP, König I, Astanina E, et al. Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biol (2009) 7:e1000025. doi:10.1371/journal.pbio.1000025
23. Yaqoob U, Cao S, Shergill U, Jagavelu K, Geng Z, Yin M, et al. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. Cancer Res (2012) 72:4047-59. doi:10.1158/0008-5472.CAN-11-3907
24. Banerjee S, Sengupta K, Dhar K, Mehta S, D'Amore PA, Dhar G, et al. Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. Mol Carcinog (2006) 45:871-80. doi:10.1002/mc.20248
25. Dhar K, Dhar G, Majumder M, Haque I, Mehta S, Van Veldhuizen PJ, et al. Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. Mol Cancer (2010) 9:209. doi:10.1186/1476-4598-9-209
26. Pellet-Many C, Frankel P, Evans IM, Herzog B, Junemann-Ramirez M, Zachary IC. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem J (2011) 435:609-18. doi:10.1042/BJ20100580
27. Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 152:1065-76. doi:10.1016/j.cell.2013.01.036
28. Evans IM, Yamaji M, Britton G, Pellet-Many C, Lockie C, Zachary IC, et al. Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells. Mol Cell Biol (2011) 31:1174-85. doi:10.1128/MCB.00903-10
29. Ruffini F, D'Atri S, Lacal PM. Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms. Int J Oncol (2013) 43:297-306. doi:10.3892/ijo.2013.1948
30. Raimondi C, Fantin A, Lampropoulou A, Denti L, Chikh A, Ruhrberg C. Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. J Exp Med (2014) 211:1167-83. doi:10.1084/jem.20132330
31. Tao Q, Spring SC, Terman BI. Characterization of a new alternatively spliced neuropilin-1 isoform. Angiogenesis (2003) 6:39-45. doi:10.1023/A:1025884628155
32. Cackowski FC, Xu L, Hu B, Cheng SY. Identification of two novel alternatively spliced neuropilin-1 isoforms. Genomics (2004) 84:82-94. doi:10.1016/j.ygeno.2004.02.001
33. Jubb AM, Strickland LA, Liu SD, Mak J, Schmidt M, Koeppen H. Neuropilin-1 expression in cancer and development. J Pathol (2012) 226:50-60. doi:10.1002/path.2989
34. Grandclement C, Borg C. Neuropilins: a new target for cancer therapy. Cancers (2011) 3:1899-928. doi:10.3390/cancers3021899
35. Hansel DE, Wilentz RE, Yeo CJ, Schulick RD, Montgomery E, Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol (2004) 28:347-56. doi:10.1097/00000478-200403000-00007
36. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res (2001) 61:5736-40.
37. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J (2000) 14:2532-9. doi:10.1096/fj.00-0250com
38. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res (2003) 63:5230-3.
39. Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer (2005) 92:328-33.
40. Chabbert-de Ponnat I, Buffard V, Leroy K, Bagot M, Bensussan A, Wolkenstein P, et al. Antiproliferative effect of semaphorin 3F on human melanoma cell lines. J Invest Dermatol (2006) 126:2343-5. doi:10.1038/sj.jid.5700382
41. Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res (2007) 13:4759-68. doi:10.1158/1078-0432.CCR-07-0001
42. Cao Y, Wang L, Nandy D, Zhang Y, Basu A, Radisky D, et al. Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res (2008) 68:8667-72. doi:10.1158/0008-5472.CAN-08-2614
43. Jia H, Cheng L, Tickner M, Bagherzadeh A, Selwood D, Zachary I. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer (2010) 102:541-52. doi:10.1038/sj.bjc.6605539
44. Erskine L, Reijntjes S, Pratt T, Denti L, Schwarz Q, Vieira JM, et al. VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. Neuron (2011) 70:951-65. doi:10.1016/j.neuron.2011.02.052
45. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol (2000) 115:1000-7. doi:10.1046/j.1523-1747.2000.00199.x
46. Lacal PM, Ruffini F, Pagani E, D'Atri S. An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol (2005) 27:1625-32. doi:10.3892/ijo.27.6.1625
47. Ruffini F, Graziani G, Levati L, Tentori L, D'Atri S, Lacal PM. Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of avß5 integrin. Int J Cancer (2015) 136:E545-58. doi:10.1002/ijc.29252
48. Ruffini F, Tentori L, Dorio AS, Arcelli D, d'Amati G, D'Atri S, et al. Platelet derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. Oncol Rep (2013) 30:2887-96. doi:10.3892/or.2013.2791
49. Marcellini M, De Luca N, Riccioni T, Ciucci A, Orecchia A, Lacal PM, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol (2006) 169:643-54. doi:10.2353/ajpath.2006.051041
50. Levati L, Ruffini F, Muzi A, Umezawa K, Graziani G, D'Atri S, et al. Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-?B. Int J Oncol (2011) 38:241-7. doi:10.3892/ijo_00000844
51. Ruffini F, Graziani G, Levati L, Tentori L, Caporali S, D'Atri S, et al. Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma. J Transl Med (2015) 13:2074. doi:10.1186/1479-5876-13-S1-P6
52. Seftor RE, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV, et al. Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol (2012) 181:1115-25. doi:10.1016/j.ajpath.2012.07.013
53. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem (2003) 278:48848-60. doi:10.1074/jbc.M310047200
54. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol (2013) 31:1219-30. doi:10.1200/JCO.2012.46.2762
55. Adham SA, Al Harrasi I, Al Haddabi I, Al Rashdi A, Al Sinawi S, Al Maniri A, et al. Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer. J Histochem Cytochem (2014) 62:619-31. doi:10.1369/0022155414538821
56. Chu W, Song X, Yang X, Ma L, Zhu J, He M, et al. Neuropilin-1 promotes epithelial-to-mesenchymal transition by stimulating nuclear factor-kappa B and is associated with poor prognosis in human oral squamous cell carcinoma. PLoS One (2014) 9:e101931. doi:10.1371/journal.pone.0101931
57. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci USA (2000) 97:2573-8. doi:10.1073/pnas.040337597
58. Panigrahy D, Adini I, Mamluk R, Levonyak N, Bruns CJ, D'Amore PA, et al. Regulation of soluble neuropilin 1, an endogenous angiogenesis inhibitor, in liver development and regeneration. Pathology (2014) 46:416-23. doi:10.1097/PAT.0000000000000121
59. Schuch G, Machluf M, Bartsch G Jr, Nomi M, Richard H, Atala A, et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. Blood (2002) 100:4622-8. doi:10.1182/blood.V100.13.4622
60. Geretti E, Klagsbrun M. Neuropilins: novel targets for anti-angiogenesis therapies. Cell Adh Migr (2007) 1:56-61. doi:10.4161/cam.1.2.4490
61. Lu Y, Xiang H, Liu P, Tong RR, Watts RJ, Koch AW, et al. Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration. MAbs (2009) 1:364-9. doi:10.4161/mabs.1.4.8885
62. Koch S, van Meeteren LA, Morin E, Testini C, Westörm S, Björkelund H, et al. NRP1 presented in trans to the endothelium arrests VEGFR2 endocytosis, preventing angiogenic signaling and tumor initiation. Dev Cell (2014) 28:633-46. doi:10.1016/j.devcel.2014.02.010
63. Joseph D, Ho SM, Syed V. Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Mol Cancer Ther (2010) 9:499-509. doi:10.1158/1535-7163.MCT-09-0664
64. Capparuccia L, Tamagnone L. Semaphorin signaling in cancer cells and in cells of the tumor microenvironment - two sides of a coin. J Cell Sci. (2009) 122:1723-36. doi:10.1242/jcs.030197
65. Tapia R, Guan F, Gershin I, Teichman J, Villegas G, Tufro A. Semaphorin3a disrupts podocyte foot processes causing acute proteinuria. Kidney Int (2008) 73:733-40. doi:10.1038/sj.ki.5002726
66. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J (2007) 26:4902-12. doi:10.1038/sj.emboj.7601906
67. Liang WC, Dennis MS, Stawicki S, Chanthery Y, Pan Q, Chen Y, et al. Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol (2007) 366:815-29. doi:10.1016/j.jmb.2006.11.021
68. Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 11:53-67. doi:10.1016/j.ccr.2006.10.018
69. Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, et al. Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin. Cancer Res (2012) 18:6040-8.
70. Zeng F, Luo F, Lv S, Zhang H, Cao C, Chen X, et al. A monoclonal antibody targeting neuropilin-1 inhibits adhesion of MCF7 breast cancer cells to fibronectin by suppressing the FAK/p130cas signaling pathway. Anticancer Drugs (2014) 25:663-72. doi:10.1097/CAD.0000000000000091
71. Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther. (2010) 3:69-82. doi:10.2147/OTT.S5256
72. Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs (2014) 32:653-60. doi:10.1007/s10637-014-0071-z
73. Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, et al. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 73:951-60. doi:10.1007/s00280-014-2426-8
74. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem (2002) 277:24818-25. doi:10.1074/jbc.M200730200
75. Jia H, Bagherzadeh A, Hartzoulakis B, Jarvis A, Löhr M, Shaikh S, et al. Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. J Biol Chem (2006) 281:13493-502. doi:10.1074/jbc.M512121200
76. Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem (1997) 272:31582-8. doi:10.1074/jbc.272.50.31582
77. Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, et al. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci (2006) 79:2370-81. doi:10.1016/j.lfs.2006.08.005
78. Giordano RJ, Cardó-Vila M, Salameh A, Anobom CD, Zeitlin BD, Hawke DH, et al. From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway. Proc Natl Acad Sci U. S. A. (2010) 107:5112-7. doi:10.1073/pnas.0915141107
79. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem (2010) 53:2215-26. doi:10.1021/jm901755g
80. Starzec A, Miteva MA, Ladam P, Villoutreix BO, Perret GY. Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening. Bioorg Med Chem (2014) 22:4042-8. doi:10.1016/j.bmc.2014.05.068
81. Bergé M, Bonnin P, Sulpice E, Vilar J, Allanic D, Silvestre JS, et al. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol (2010) 177:3192-201. doi:10.2353/ajpath.2010.100157
82. Raskopf E, Vogt A, Standop J, Sauerbruch T, Schmitz V. Inhibition of neuropilin-1 by RNA-interference and its angiostatic potential in the treatment of hepatocellular carcinoma. Z Gastroenterol (2010) 48:21-7. doi:10.1055/s-0028-1109907
83. Lu L, Zhang L, Xiao Z, Lu S, Yang R, Han ZC. Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma (2008) 49:331-8. doi:10.1080/10428190701809149
84. West DC, Rees CG, Duchesne L, Patey SJ, Terry CJ, Turnbull JE, et al. Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. J Biol Chem (2005) 280:13457-64. doi:10.1074/jbc.M410924200
85. Cui Y, Han Z, Hu Y, Song G, Hao C, Xia H, et al. MicroRNA-181b and microRNA-9 mediate arsenic-induced angiogenesis via NRP1. J Cell Physiol. (2012) 227:772-83. doi:10.1002/jcp.22789
86. Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC, Hong TM. miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1. Angiogenes1is (2014) 17:247-60. doi:10.1007/s10456-013-9394-1
87. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, et al. microRNA-320a inhibits tumor invasion by targeting neuropilin1 and is associated with liver metastasis in colorectal cancer. Oncol Rep (2012) 27:685-94. doi:10.3892/or.2011.1561
88. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 16:510-20. doi:10.1016/j.ccr.2009.10.013
89. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA. (2009) 106:16157-62. doi:10.1073/pnas.0908201106
90. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, et al. Targeting neuropilin-1 in human leukemia and lymphoma. Blood (2011) 117:920-7. doi:10.1182/blood-2010-05-282921
91. Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene (2011) 31(33):3754-63. doi:10.1038/onc.2011.537
92. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 328:1031-5. doi:10.1126/science.1183057
93. Dai W, Fan Y, Zhang H, Wang X, Zhang Q, Wang X. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Drug Del. (2015) 22:10-20. doi:10.3109/10717544.2014.903580
94. Kumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, et al. Gold nanoparticles functionalized with therapeutic andtargeted peptides for cancer treatment. Biomaterials (2012) 33:1180-9. doi:10.1016/j.biomaterials.2011.10.058
95. Tentori L, Lacal PM, Graziani G. Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol Sci (2013) 34:656-66. doi:10.1016/j.tips.2013.10.003
96. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res (2009) 19:275-82. doi:10.1097/CMR.0b013e32832eabd5
97. Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol (2012) 8:viii10-4. doi:10.1093/annonc/mds257
98. Edelbauer M, Datta D, Vos IH, Basu A, Stack MP, Reinders ME, et al. Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood (2010) 116:1980-9. doi:10.1182/blood-2009-11-252460
99. Suzuki T, Hirakawa S, Shimauchi T, Ito T, Sakabe J, Detmar M, et al. VEGF-A promotes IL-17A-producing γ?δ T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci (2014) 74:116-24. doi:10.1016/j.jdermsci.2013.12.013
100. Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, Kliche S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med (2012) 209:2001-16. doi:10.1084/jem.20111497
101. Ladányi A. Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res (2015). doi:10.1111/pcmr.12371
102. Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch'ng E, et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature (2002) 419:629-33. doi:10.1038/nature01037
103. Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature (2013) 501:252-6. doi:10.1038/nature12428
104. Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, et al. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 166:368-77. doi:10.1111/j.1476-5381.2011.01777.x
105. Bondeva T, Wojciech S, Wolf G. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner. Am J Physiol Renal Physiol (2011) 301:F852-70. doi:10.1152/ajprenal.00575.2010